Drugs / Anlotinib Hydrochloride Capsules
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03940378 Background | Feb 2019 → Feb 2023 | — | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anlotinib Hydrochloride Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03940378 ↗ |
| Route | Oral | “12mg/d; po;” NCT03940378 ↗ |